While this research continues, however, we have a responsibility to ensure that women with advanced ovarian cancer who are candidates for IP therapy benefit from this treatment advance associated with such a remarkable improvement in overall survival . This statement was printed in the January, 2006 National Cancer Institute's (NCI), Division of Cancer Treatment and Diagnosis announcement concerning the survival benefits of intraperitoneal chemotherapy for stage III ovarian cancer [1, 2]. Despite the efforts of the NCI, the Gynecologic Oncology Group (GOG), the Society for Gynecologic Oncology (SGO), and the American Society of Clinical Oncology (ASCO) to educate gynecologic and medical oncologists concerning the remarkable efficacy of intraperitoneal chemotherapy and the way it should be administered, the majority of women with stage III, optimally debulked disease, are not being offered or treated with intraperitoneal chemotherapy .
|Original language||English (US)|
|Title of host publication||Intraperitoneal Therapy for Ovarian Cancer|
|Publisher||Springer Berlin Heidelberg|
|Number of pages||6|
|State||Published - 2010|
ASJC Scopus subject areas